Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis

Press Release

Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 11, 2026, 07:30 ET Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing the first Multi-Target…

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum

Press Release

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Feb 18, 2026, 07:30 ET New program expands pipeline derived from Alphyn’s proprietary multi-target drug platform ANNAPOLIS, Md., Feb. 18, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,…

Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

Press Release

Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline NEWS PROVIDED BY Alphyn Biologics Dec 12, 2025, 07:30 ET Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing…

Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic

Press Release

Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic NEWS PROVIDED BY Alphyn Biologics Oct 27, 2025, 07:30 ET Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office…

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal

Press Release

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal NEWS PROVIDED BY Alphyn Biologics Jul 01, 2025, 07:30 ET Expert dermatologist panel creates new atopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD’s intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization…